title: Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
abstract: The objective of this subanalysis of the Phase III DUET trials was to examine virological response to an etravirine-containing regimen in patients harbouring virus fully sensitive to etravirine. Full etravirine sensitivity was defined as fold change in 50% effective concentration (FC) ≤3 or weighted genotypic score ≤2. At Week 48 in the etravirine group, 74% of patients with etravirine FC ≤3 and 77% with etravirine genotypic score ≤2 had viral load <50 HIV-1 RNA copies/mL, versus 48% and 46%, respectively, in the placebo group (P < 0.0001). Response rates increased with baseline phenotypic sensitivity score, but were consistently higher with etravirine (56-82%) than placebo (2-72%). Similar observations were made in patients harbouring virus with full etravirine and darunavir sensitivity. Our findings support current recommendations to include three active agents in treatment-experienced patients' regimens.
authors.affiliation: Division of Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium. nathan_clumeck@stpierre-bru.be
authors.forename: N
authors.initials: N
authors.lastname: Clumeck
authors.forename: P
authors.initials: P
authors.lastname: Cahn
authors.forename: J-M
authors.initials: JM
authors.lastname: Molina
authors.forename: A
authors.initials: A
authors.lastname: Mills
authors.forename: S
authors.initials: S
authors.lastname: Nijs
authors.forename: J
authors.initials: J
authors.lastname: Vingerhoets
authors.forename: J
authors.initials: J
authors.lastname: Witek
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D000069454:Darunavir; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000254:growth & development*; D006801:Humans; D009570:Nitriles; D010641:Phenotype; D011724:Pyridazines / Q000008:administration & dosage*; D011743:Pyrimidines; D012367:RNA, Viral / Q000097:blood; D013449:Sulfonamides / Q000008:administration & dosage; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D012367:RNA, Viral; D013449:Sulfonamides; C451734:etravirine; D000069454:Darunavir